Table 2.
All participants with pretreatment drug resistance mutations
| Sample | Age | Subtype | Targeting drugs of resistant mutations | ||
|---|---|---|---|---|---|
| NRTIs | NNRTIs | PIs | |||
| 076 | 58 | B | K103 N | ||
| 098a | 65 | B | K103 N | ||
| 132a | 52 | B | K103 N | ||
| 134a | 56 | B | K103 N | ||
| 135a | 56 | B | K103 N | ||
| 322 | 71 | 01_AE | K103 N | ||
| 373 | 72 | B | K103 N、K101E | ||
| 059 | 37 | 07_BC | M184 V | ||
| 063 | 47 | 01_AE | K103 N、L100I | ||
| 064 | 46 | 01_AE | K103 N、L100I | ||
| 166 | 43 | 07_BC | K219 N | Y181C | |
| 173 | 43 | 01_AE | M46 L | ||
| 231a | 48 | B | K103 N | ||
| 263 | 46 | B | K103 N | ||
| 343 | 36 | 07_BC | V106 M | ||
| 345 | 34 | 08_BC | G190A | ||
PI protease inhibitors, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors; “a”, sequences in local transmission clusters